|
|
|
| Clinical effect of Qishenhuanwu Capsules on Parkinson’s disease with qi and blood deficiency |
| WANG Wen1 QIU Zhixin1 ZHENG Jianbiao1 JING Haifang1 WANG Aiqing1 LIU Dongfang1 LI Ning1 WNAG Yingli2 |
1.The Second Department of Encephalopathy, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Hebei Province, Changzhou 061000, China;
2.Teaching and Research Section of Internal Medicine, Cangzhou Medical College, Hebei Province, Changzhou 061001, China
|
|
|
|
Abstract Objective To explore the clinical effect of Qishenhuanwu Capsules in treating Parkinson’s disease (PD) with Qi and blood deficiency. Methods A total of 100 PD patients with Qi and blood deficiency admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from March 2020 to January 2022 were selected and divided into control group (conventional drug treatment, 50 cases) and experimental group (conventional drug treatment combined with Qishenhuanwu Capsules, 50 cases) by random number table method. The two groups were treated for a total of six weeks. The clinical effects, motor and non-motor symptoms before and after treatment, and related laboratory indicators were compared between the two groups. Results The clinical efficacy of the experimental group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, the scores of the Simple Intelligent Mental State Assessment Scale and the Montreal Cognitive Assessment Scale in the two groups were higher than before treatment, while those of the experimental group were higher than those of the control group, and the differences were statistically significant (P＜0.05). After treatment, PD rating scale Ⅲ and PD non-motor symptom questionnaire scores of the two groups were lower than before treatment, and those of the experimental group were lower than the control group, and the differences were statistically significant (P＜0.05). After treatment, serum insulin-like growth factor and β-amyloid 1-42 in two groups were higher than before treatment, while those of the experimental group were higher than those of the control group; homocysteine and C-reactive protein in the two groups were lower than before treatment, while those of the experimental group were lower than those of the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Qishenhuanwu Capsules can effectively improve motor and non-motor symptoms of PD patients with qi and blood deficiency, the effect is remarkable.
|
|
|
|
|
|
[1] 王伟，曹庆华，孙光玲，等.脑白质病变与帕金森病患者运动症状及非运动症状的相关性分析[J].中华全科医学，2022，20（2）：237-239.
[2] 史宝燕，李彦，李玥.中西药联合治疗帕金森病的研究进展[J].中国药事，2021，35（11）：1269-1275.
[3] 徐栋，袁永娥，黄世敬.基于中医传承辅助平台探讨培元通滞法治疗帕金森病的用药规律[J].医学综述，2022，28（7）：1419-1424.
[4] 景海芳，王雯，邱志新，等.芪参还五胶囊对气血亏虚型帕金森病患者UPDRS评分及平衡能力的影响[J].中华老年多器官疾病杂志，2022，21（1）：29-33.
[5] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[6] 隆呈祥.中医老年颤证诊断及疗效评定标准[J].北京中医学院学报，1992，15（4）：39.
[7] 邵文丽，赵羚，吴凡，等.蒙特利尔认知评估量表在老年神经认知障碍中的诊断价值[J].中国老年学杂志，2021， 41（16）：3551-3554.
[8] Galea M，Woodward M. Mini-Mental State Examination （MMSE） [J]. Aust J Physiother，2005，51（3）：198.
[9] 王坚，蒋雨平，管一晖，等.帕金森病患者临床量表UPDRS与18F-FP-CIT PET-DAT功能显像相关性的研究[J].中国临床神经科学，2003，11（4）：329-332.
[10] 王雅洁，刘卫国，于翠玉，等.帕金森病初诊患者的非运动症状特点及其性别差异[J].中风与神经疾病杂志，2022，39（1）：28-32.
[11] 中华全国中医学会老年医学会.中医老年颤证诊断和疗效评定标准[J].北京中医学院学报，1992，15（4）：40- 41.
[12] 韩世友.“控帕汤”联合美多巴治疗气血亏虚型帕金森病的临床研究[J].中华中医药学刊，2014，32（1）：161- 163.
[13] 姚璇，时晶，李婷，等.帕金森病疲劳症状中医证候要素特征分析[J].天津中医药，2021，38（10）：1259-1262.
[14] 孙雪，梁建庆，何建成，等.帕金森病的中医辨证治疗[J].西部中医药，2021，34（2）：131-133.
[15] 郑建彪，郑娜，王雯，等.芪参还五胶囊治疗气虚血瘀型后循环缺血性眩晕的临床疗效观察[J].中西医结合心脑血管病杂志，2018，16（16）：2396-2397.
[16] 张家和，柯开富，施建生，等.血尿酸、CysC及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析[J].中国医药导报，2022，19（5）：82-85.
[17] 宋卫科，郑荐，杨晓樨.血清IGF-1，5-HT及TNF-α水平与帕金森病伴发抑郁的相关性[J].临床与病理杂志，2020，40（12）：3171-3176.
[18] 邢效如，郝雅男，孙志，等.帕金森病患者血清胱抑素C、β-淀粉样蛋白1-42检测的临床意义[J].现代生物医学进展，2020，20（8）：1561-1564，1568.
[19] 王昌权，田宇，周刚，等.帕金森患者血清Aβ1-42含量与炎症因子及受体、抗氧化酶的相关性研究[J].海南医学院学报，2018，24（1）：138-140，144.
[20] 张煜，董金霞，李青，等.老年帕金森病患者血清Aβ1- 42、EGF和Hcy水平与认知功能障碍及疾病严重程度的关系及其预测价值分析[J].现代生物医学进展，2022， 22（11）：2186-2190.
[21] 石强，罗琴，龚亲平，等.重复经颅磁刺激联合“氧-针-康”方案对帕金森病患者运动功能以及血清C反应蛋白和血浆多巴胺的影响[J].中国全科医学，2020，23（27）：3460-3465.
[22] 宋文婷，苗兰，孙明谦，等.益气活血方及其拆方对气虚血瘀型脑梗大鼠影响的比较研究[J].中国中医基础医学杂志，2021，27（6）：921-926.
[23] 王开达，王兴臣，姬琳.网络药理学预测黄芪治疗帕金森病作用机制及实验验证[J].中国实验方剂学杂志，2020，26（24）：178-185.
[24] 洒晓亮，高之苑，张兰.基于网络药理学探讨太子参、赤芍治疗糖尿病合并冠心病的作用机制[J].中西医结合心脑血管病杂志，2020，18（13）：2017-2023.
[25] 辛高杰，付建华，韩笑，等.基于网络药理学的桃仁-红花药对治疗缺血性心脏病机制研究[J].中国中医药信息杂志，2020，27（11）：106-110. |
|
|
|
